Zymeworks (ZYME) is in focus after new Phase 1 data for its FRa-targeting ADC ZW191 in heavily pretreated ovarian cancer, as well as a global collaboration with Roche around trispecific T cell engager...
Source LinkZymeworks (ZYME) is in focus after new Phase 1 data for its FRa-targeting ADC ZW191 in heavily pretreated ovarian cancer, as well as a global collaboration with Roche around trispecific T cell engager...
Source Link
Comments